Dear BSBMTCT member,
We hope you are keeping well now the nights are drawing in and the air is starting to feel distinctly chillier.
A few updates this month…
- We had a very successful hybrid BSBMTCT Education Day this month on November 1 with a range of international speakers, including key friend from EBMT, including Anna Sureda (President), Fabio Ciceri, and Per Ljungman with their world leading expertise. Especially stimulating was the session on EDI chaired by Orin Lewis, chair of the ACLT, with crucial and original discussion from Nada Hamad (Australia) and Claire Horgan (EBMT Trainees Committee). Terri McVeigh (RMH) and Angela Hamblin (NHSE Genomics & Oxford) provided current insights into the state of the art in germline testing and its implications for BMT patients and donors. Also many thanks to Angela Halley (RMH) for a thoroughly useful summary of the place of Palliative Medicine in HCT. Finally, many thanks to David Marks, previously a BSBMT President for delivering with Anna Castleton, an excellent summary of where we have come from and where we are heading with HSCT, CAR-T and other therapies in ALL. The meeting was very well attended and received excellent feedback. A few nice pics at the end of this Bulletin – and all our very best to David on his (busy) retirement!
- The deadline for the vacancies for the President Elect and ACT and Vaccination Sub Committee chairs has now passed and we have received nominations for each role. Thank you to those who put themselves up for the 3 new roles within the BSBMTCT Executive, the voting papers are now out to centre programme directors, who have 1 vote each. The deadline to submit your votes is Monday 5th We will announce the results on the 6th December and the successful appointee will start in January 2023.
- The Joint Consensus Statement on the Vaccination of Adult and Paediatric Haematopoietic Stem Cell Transplant Recipients. Prepared on Behalf of the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT), the Children’s Cancer and Leukaemia Group (CCLG), and British Infection Association (BIA) published on the 14th November 2022 can be found here https://www.journalofinfection.com/article/S0163-4453(22)00646-6/fulltext. We remember the immense contribution of the late Paul Miller, who with Thushan de Silva, Andy Clark and others in BSBMTCT and allied organisations have brought this essential guideline to publication in a high impact factor journal.
- Ruxolitinib‘campaign’ – we continue to lobby with Anthony Nolan and others to restore funded access to Ruxolitinib for graft-versus-host-disease. Please see the BSBMTCT Position Statement on our website on this issue.
- Our Equality, Diversity and Inclusion (EDI)survey will circulated soon and provide invaluable information for the future of our Society, as well as meeting various requirements as a professional and charitable organisation.
Otherwise please save the dates for the upcoming BSBMTCT events :
- BSBMTCT Scientific Day 2023Wednesday 17 May 2023, as a hybrid meeting
- BSBMTCT Scientific showcase for Advanced Cell Therapy (ACT) subcommittee 2023with the provisional date Monday 19th June
Our very best wishes
John Snowden, Kim Orchard, Fiona Dignan, Deborah Richardson, Eduardo Olavarria, & Julia Lee